IMMIX BIOPHARMA, INC. Financing Cash Flow
IMMIX BIOPHARMA, INC. (IMMX) reported Financing Cash Flow of $155.25 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-07
- IMMIX BIOPHARMA, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $155.28M.
- IMMIX BIOPHARMA, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$37.56K.
- IMMIX BIOPHARMA, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $95.67M.
- IMMIX BIOPHARMA, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $10.61M.
- IMMIX BIOPHARMA, INC. net cash provided by (used in) financing activities for fiscal 2025 was $107.39M, a 573.33% increase from fiscal 2024.
- IMMIX BIOPHARMA, INC. net cash provided by (used in) financing activities for fiscal 2024 was $15.95M, a 3.14% increase from fiscal 2023.
- IMMIX BIOPHARMA, INC. net cash provided by (used in) financing activities for fiscal 2023 was $15.46M, a 378.44% increase from fiscal 2022.
- IMMIX BIOPHARMA, INC. net cash provided by (used in) financing activities for fiscal 2022 was $3.23M, a 82.85% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $155.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $155.25M 10-Q · filed 2026-08-07 | $250.91M derived: sum of 3 quarters · filed 2026-08-07 | $261.52M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$37.56K 10-Q · filed 2026-05-07 | $95.63M derived: sum of 2 quarters · filed 2026-05-07 | $106.24M derived: sum of 3 quarters · filed 2026-05-07 | |
| 2025-12-31 | $95.67M derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | $106.28M derived: sum of 2 quarters · filed 2026-03-27 | $107.39M 10-K/A · filed 2026-03-27 | |
| 2025-09-30 | $10.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $11.72M 10-Q · filed 2025-11-07 | ||
| 2025-06-30 | $1.11M 10-Q · filed 2026-08-07 | |||
| 2024-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | $0.00 derived: sum of 2 quarters · filed 2026-03-27 | $0.00 derived: sum of 3 quarters · filed 2026-03-27 | $15.95M 10-K/A · filed 2026-03-27 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $15.95M 10-Q · filed 2025-11-07 | $16.54M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $15.95M 10-Q · filed 2025-08-08 | $16.54M derived: sum of 3 quarters · filed 2025-08-08 | $26.60M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $15.95M 10-Q · filed 2025-05-08 | $16.54M derived: sum of 2 quarters · filed 2025-05-08 | $26.60M derived: sum of 3 quarters · filed 2025-05-08 | $31.29M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $586.69K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $10.65M derived: sum of 2 quarters · filed 2025-03-25 | $15.34M derived: sum of 3 quarters · filed 2025-03-25 | $15.46M 10-K · filed 2025-03-25 |
| 2023-09-30 | $10.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $14.76M derived: sum of 2 quarters · filed 2024-11-12 | $14.88M 10-Q · filed 2024-11-12 | $15.30M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $4.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $4.81M 10-Q · filed 2024-08-12 | $5.23M derived: sum of 3 quarters · filed 2024-08-12 | $5.23M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $118.92K 10-Q · filed 2024-05-09 | $543.19K derived: sum of 2 quarters · filed 2024-05-09 | $543.19K derived: sum of 3 quarters · filed 2024-05-09 | $437.23K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $424.28K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $424.28K derived: sum of 2 quarters · filed 2024-03-29 | $318.31K derived: sum of 3 quarters · filed 2024-03-29 | $3.23M 10-K · filed 2024-03-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$105.96K derived: sum of 2 quarters · filed 2023-11-13 | $2.81M 10-Q · filed 2023-11-13 | $21.53M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$105.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $2.81M 10-Q · filed 2023-08-11 | $21.53M derived: sum of 3 quarters · filed 2023-08-11 | $21.51M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $2.91M 10-Q · filed 2023-05-12 | $21.63M derived: sum of 2 quarters · filed 2023-05-12 | $21.62M derived: sum of 3 quarters · filed 2023-05-12 | $21.70M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $18.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $18.70M derived: sum of 2 quarters · filed 2023-03-27 | $18.78M derived: sum of 3 quarters · filed 2023-03-27 | $18.85M 10-K · filed 2023-03-27 |
| 2021-09-30 | -$18.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $63.98K derived: sum of 2 quarters · filed 2022-11-09 | $128.98K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $82.33K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $147.33K 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $65.00K 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |